Cargando…
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/ https://www.ncbi.nlm.nih.gov/pubmed/35611683 http://dx.doi.org/10.1002/ehf2.13955 |
_version_ | 1784748529136173056 |
---|---|
author | Thiele, Kirsten Rau, Matthias Hartmann, Niels‐Ulrik Korbinian Möller, Marcus Möllmann, Julia Jankowski, Joachim Keszei, András P. Böhm, Michael Floege, Jürgen Marx, Nikolaus Lehrke, Michael |
author_facet | Thiele, Kirsten Rau, Matthias Hartmann, Niels‐Ulrik Korbinian Möller, Marcus Möllmann, Julia Jankowski, Joachim Keszei, András P. Böhm, Michael Floege, Jürgen Marx, Nikolaus Lehrke, Michael |
author_sort | Thiele, Kirsten |
collection | PubMed |
description | AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP‐2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF. |
format | Online Article Text |
id | pubmed-9288802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92888022022-07-19 Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure Thiele, Kirsten Rau, Matthias Hartmann, Niels‐Ulrik Korbinian Möller, Marcus Möllmann, Julia Jankowski, Joachim Keszei, András P. Böhm, Michael Floege, Jürgen Marx, Nikolaus Lehrke, Michael ESC Heart Fail Short Communications AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP‐2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)(2)/1000; empagliflozin: 0.3 ± 0.2 (ng/mL)(2)/1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF. John Wiley and Sons Inc. 2022-05-25 /pmc/articles/PMC9288802/ /pubmed/35611683 http://dx.doi.org/10.1002/ehf2.13955 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Short Communications Thiele, Kirsten Rau, Matthias Hartmann, Niels‐Ulrik Korbinian Möller, Marcus Möllmann, Julia Jankowski, Joachim Keszei, András P. Böhm, Michael Floege, Jürgen Marx, Nikolaus Lehrke, Michael Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title_full | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title_fullStr | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title_full_unstemmed | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title_short | Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
title_sort | empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/ https://www.ncbi.nlm.nih.gov/pubmed/35611683 http://dx.doi.org/10.1002/ehf2.13955 |
work_keys_str_mv | AT thielekirsten empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT raumatthias empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT hartmannnielsulrikkorbinian empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT mollermarcus empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT mollmannjulia empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT jankowskijoachim empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT keszeiandrasp empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT bohmmichael empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT floegejurgen empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT marxnikolaus empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure AT lehrkemichael empagliflozinreducesmarkersofacutekidneyinjuryinpatientswithacutedecompensatedheartfailure |